TMEM132C

Summary

TMEM132C (transmembrane protein 132C, HGNC:25436) is a protein-coding gene on chromosome 12q24.32, encoding Transmembrane protein 132C (Q8N3T6).

Predicted to be located in membrane.

Source: NCBI Gene 92293 — RefSeq curated summary.

At a glance

• GWAS associations: 13
• Clinical variants (ClinVar): 230 total
• MANE Select transcript: NM_001136103

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25436
Approved symbol	TMEM132C
Name	transmembrane protein 132C
Location	12q24.32
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp761O2018, PPP1R152
Ensembl gene	ENSG00000181234
Ensembl biotype	protein_coding
Entrez	92293

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000435159

RefSeq mRNA: 2 — MANE Select: NM_001136103 NM_001136103, NM_001387058

CCDS: CCDS45009

Canonical transcript exons

ENST00000435159 — 9 exons

Exon	Start	End
ENSE00001253765	128697224	128697415
ENSE00001298489	128669417	128669560
ENSE00001646532	128543957	128544103
ENSE00001757971	128414732	128415620
ENSE00002248933	128267170	128267487
ENSE00002275110	128705090	128707911
ENSE00002383779	128693829	128694034
ENSE00003676205	128695830	128696103
ENSE00003692651	128616152	128616335

Expression profiles

Bgee: expression breadth ubiquitous, 199 present calls, max score 94.99.

FANTOM5 (CAGE): breadth broad, TPM avg 2.5155 / max 147.1385, expressed in 345 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
128699	2.5155	345

Top tissues by expression

242 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
decidua	UBERON:0002450	94.99	gold quality
buccal mucosa cell	CL:0002336	90.20	gold quality
upper arm skin	UBERON:0004263	89.50	gold quality
epithelial cell of pancreas	CL:0000083	89.33	silver quality
left ventricle myocardium	UBERON:0006566	87.88	gold quality
oviduct epithelium	UBERON:0004804	85.72	gold quality
adipose tissue	UBERON:0001013	85.71	gold quality
middle temporal gyrus	UBERON:0002771	85.69	gold quality
endocervix	UBERON:0000458	85.05	gold quality
kidney epithelium	UBERON:0004819	84.59	gold quality
subcutaneous adipose tissue	UBERON:0002190	84.48	gold quality
lateral nuclear group of thalamus	UBERON:0002736	84.34	gold quality
endothelial cell	CL:0000115	84.21	silver quality
parietal pleura	UBERON:0002400	84.13	gold quality
Brodmann (1909) area 23	UBERON:0013554	83.40	gold quality
adipose tissue of abdominal region	UBERON:0007808	82.71	gold quality
medial globus pallidus	UBERON:0002477	82.32	gold quality
substantia nigra pars compacta	UBERON:0001965	82.27	gold quality
lateral globus pallidus	UBERON:0002476	82.13	gold quality
globus pallidus	UBERON:0001875	82.12	gold quality
peritoneum	UBERON:0002358	82.09	gold quality
omental fat pad	UBERON:0010414	82.09	gold quality
fallopian tube	UBERON:0003889	81.84	gold quality
postcentral gyrus	UBERON:0002581	81.53	gold quality
thoracic mammary gland	UBERON:0005200	81.52	gold quality
left uterine tube	UBERON:0001303	81.42	gold quality
mammary gland	UBERON:0001911	81.26	gold quality
entorhinal cortex	UBERON:0002728	81.09	gold quality
endometrium	UBERON:0001295	80.67	gold quality
ectocervix	UBERON:0012249	80.65	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	70.78
E-HCAD-25	yes	19.74
E-ANND-3	yes	5.43

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

69 targeting TMEM132C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-221-3P	99.86	71.56	1329
HSA-MIR-222-3P	99.86	71.35	1337
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-26B-5P	99.78	73.51	2305
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-623	99.76	68.16	1170
HSA-MIR-187-5P	99.74	70.26	1404
HSA-MIR-2116-3P	99.74	64.32	889
HSA-MIR-4465	99.71	72.56	2096
HSA-MIR-1197	99.70	67.75	1027
HSA-MIR-1283	99.69	72.42	3009

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	TMEM132C	ENSDARG00000062538
danio_rerio	TMEM132C	ENSDARG00000074863
danio_rerio	TMEM132C	ENSDARG00000075277
mus_musculus	Tmem132c	ENSMUSG00000034324
rattus_norvegicus	Tmem132c	ENSRNOG00000000963
drosophila_melanogaster	dtn	FBGN0262730
caenorhabditis_elegans		WBGENE00022175

Paralogs (4): TMEM132A (ENSG00000006118), TMEM132B (ENSG00000139364), TMEM132D (ENSG00000151952), TMEM132E (ENSG00000181291)

Protein

Protein identifiers

Transmembrane protein 132C — Q8N3T6 (reviewed: Q8N3T6)

All UniProt accessions (1): Q8N3T6

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

Similarity. Belongs to the TMEM132 family.

RefSeq proteins (2): NP_001129575, NP_001373987 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026307	TMEM132	Family
IPR031435	TMEM132_N	Domain
IPR031436	TMEM132_C	Domain
IPR031437	Ig_TMEM132_4th	Domain
IPR055421	TMEM132_3rd	Domain
IPR055422	Ig_TMEM132_2nd	Domain
IPR055423	Ig_TMEM132_5th	Domain
IPR055424	Ig_TMEM132_6th	Domain

Pfam: PF15705, PF15706, PF16070, PF23039, PF23481, PF23486, PF23487

UniProt features (17 total): sequence variant 7, topological domain 2, region of interest 2, glycosylation site 2, signal peptide 1, chain 1, transmembrane region 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N3T6-F1	69.84	0.34

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 316, 373

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 54 (showing top): WONG_ENDMETRIUM_CANCER_DN, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_DN, chr12q24, BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_B, LEE_BMP2_TARGETS_UP, MIR7_1_3P, MIR7_2_3P, MIR1297, MIR4753_3P, MIR1283, MIR6124, MIR130A_5P, MIR629_3P, MIR187_5P

GO Biological Process (1): biological_process (GO:0008150)

GO Molecular Function (1): molecular_function (GO:0003674)

GO Cellular Component (2): membrane (GO:0016020), cellular_component (GO:0005575)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	1

Protein interactions and networks

STRING

844 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMEM132C	PRAC2	D3DTV9	526
TMEM132C	TDRD10	Q5VZ19	513
TMEM132C	INPP5J	Q15735	489
TMEM132C	LRRC38	Q5VT99	475
TMEM132C	FREM3	P0C091	460
TMEM132C	CNTNAP5	Q8WYK1	447
TMEM132C	LYST	Q99698	442
TMEM132C	TAFA5	Q7Z5A7	413
TMEM132C	CACNA2D1	P54289	406
TMEM132C	RYR2	Q92736	404
TMEM132C	OR4N5	Q8IXE1	401
TMEM132C	DSCAM	O60469	389
TMEM132C	OR51I2	Q9H344	383
TMEM132C	OR4K14	Q8NGD5	380
TMEM132C	GLT1D1	Q96MS3	377
TMEM132C	ARL14	Q8N4G2	377

IntAct

4 interactions, top by confidence:

A	B	Type	Score
MAP1LC3A	TMEM132C	psi-mi:“MI:0407”(direct interaction)	0.440
TMEM132C	PPP1CA	psi-mi:“MI:0407”(direct interaction)	0.440
TMEM132C	RPL19	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (4): TMEM132C (Proximity Label-MS), TMEM132C (Protein-peptide), TMEM132C (Cross-Linking-MS (XL-MS)), TMEM132C (Affinity Capture-Western)

ESM2 similar proteins: A1A4M2, A4IFG4, A5D8P8, A6NKD9, A7E2M3, B4F7F3, E9Q6B2, F1MX48, F1SAM7, O97676, P18065, P36956, P47877, P49705, P56720, P56873, Q00709, Q00973, Q09200, Q0IHY5, Q15465, Q24JP5, Q2YD98, Q3TAS6, Q58CS8, Q5QQ49, Q5UCC4, Q60416, Q60698, Q641Q3, Q68FE7, Q6AYH6, Q6DVA0, Q6P7K5, Q6UKI2, Q6WVG3, Q80WF4, Q8IW70, Q8JGM4, Q8K064

Diamond homologs: L7VG99, Q14C87, Q14DG7, Q24JP5, Q6IEE6, Q6IEE7, Q76HP2, Q76HP3, Q80WF4, Q8CEF9, Q8N3T6, Q922P8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

230 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	200
Likely benign	21
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

3749 predictions. Top by Δscore:

Variant	Effect	Δscore
12:128267484:AAAGG:A	donor_loss	1.0000
12:128267485:AAGG:A	donor_loss	1.0000
12:128267486:AGG:A	donor_loss	1.0000
12:128267487:GGTAA:G	donor_loss	1.0000
12:128267488:GTAA:G	donor_loss	1.0000
12:128267489:T:G	donor_loss	1.0000
12:128292405:GTT:G	donor_gain	1.0000
12:128415619:AGGTA:A	donor_loss	1.0000
12:128415621:G:GA	donor_loss	1.0000
12:128415622:T:A	donor_loss	1.0000
12:128543941:A:AG	acceptor_gain	1.0000
12:128543942:T:G	acceptor_gain	1.0000
12:128543947:A:AG	acceptor_gain	1.0000
12:128543948:T:G	acceptor_gain	1.0000
12:128543953:ACAG:A	acceptor_loss	1.0000
12:128543954:C:G	acceptor_gain	1.0000
12:128543954:CA:C	acceptor_loss	1.0000
12:128543955:A:AG	acceptor_gain	1.0000
12:128543955:A:T	acceptor_loss	1.0000
12:128543956:G:GC	acceptor_gain	1.0000
12:128543956:GA:G	acceptor_gain	1.0000
12:128543956:GAGC:G	acceptor_gain	1.0000
12:128543956:GAGCC:G	acceptor_gain	1.0000
12:128544100:ACAGG:A	donor_loss	1.0000
12:128544101:CAGG:C	donor_loss	1.0000
12:128544103:GGT:G	donor_loss	1.0000
12:128544104:G:C	donor_loss	1.0000
12:128544104:G:GG	donor_gain	1.0000
12:128544105:T:A	donor_loss	1.0000
12:128616150:A:AG	acceptor_gain	1.0000

AlphaMissense

7252 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:128616237:T:A	W403R	0.998
12:128616237:T:C	W403R	0.998
12:128694006:T:A	W543R	0.998
12:128694006:T:C	W543R	0.998
12:128694008:G:C	W543C	0.997
12:128694008:G:T	W543C	0.997
12:128705757:T:A	L930H	0.997
12:128705768:T:C	F934L	0.997
12:128705770:C:A	F934L	0.997
12:128705770:C:G	F934L	0.997
12:128705789:T:C	F941L	0.997
12:128705791:C:A	F941L	0.997
12:128705791:C:G	F941L	0.997
12:128706134:T:C	F1056L	0.997
12:128706136:T:A	F1056L	0.997
12:128706136:T:G	F1056L	0.997
12:128697254:G:C	A654P	0.996
12:128705771:T:C	C935R	0.995
12:128693989:T:C	L537P	0.994
12:128694011:G:C	R544S	0.994
12:128694011:G:T	R544S	0.994
12:128705303:T:A	C779S	0.994
12:128705304:G:C	C779S	0.994
12:128705757:T:C	L930P	0.994
12:128415167:C:A	A174D	0.993
12:128616239:G:C	W403C	0.993
12:128616239:G:T	W403C	0.993
12:128695882:T:A	C570S	0.993
12:128695883:G:C	C570S	0.993
12:128695916:T:A	V581D	0.993

dbSNP variants (sampled 300 via entrez): RS1000000618 (12:128662269 A>G), RS1000006108 (12:128397766 A>G), RS1000006890 (12:128360854 G>A), RS1000015878 (12:128291298 C>G,T), RS1000017653 (12:128503719 A>C), RS1000026281 (12:128327110 A>T), RS1000027506 (12:128280603 A>G), RS1000028701 (12:128667134 CATAT>C), RS1000032813 (12:128511202 C>T), RS1000033979 (12:128315186 C>A,T), RS1000043178 (12:128516125 C>T), RS1000047236 (12:128666684 G>A), RS1000048925 (12:128634836 G>A), RS1000064224 (12:128401981 T>C), RS1000066765 (12:128514642 A>G)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): megacolon (MONDO:0001273)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST001015_3	Suicide attempts in bipolar disorder	1.000000e-06
GCST001885_3	Height	3.000000e-06
GCST002179_1	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)	2.000000e-07
GCST003075_14	Cognitive decline rate in late mild cognitive impairment	6.000000e-07
GCST003599_14	Systemic lupus erythematosus	2.000000e-06
GCST004747_18	Lung cancer in never smokers	2.000000e-07
GCST005751_11	Empathy quotient	4.000000e-08
GCST006069_66	Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)	5.000000e-06
GCST006585_960	Blood protein levels	3.000000e-27
GCST008822_3	Neuritic plaque	4.000000e-06
GCST008952_3	High chromosomal aberration frequency (chromatid type)	5.000000e-06
GCST010562_2	Depressive symptoms x herpes simplex 1 infection interaction	2.000000e-08
GCST011065_6	Levodopa-induced dyskinesia in levodopa treated Parkinson’s disease	2.000000e-06

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004321	attempted suicide
EFO:0007710	cognitive decline measurement
EFO:0009183	empathy measurement
EFO:0007934	creatinine clearance measurement
EFO:0006798	neuritic plaque measurement
EFO:0009862	chromatid-type aberration frequency
EFO:0007006	depressive symptom measurement
EFO:0007036	herpes virus seropositivity
EFO:0010747	response to levodopa

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008531	Megacolon	C06.405.469.158.701

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	3
Benzo(a)pyrene	affects methylation, increases expression	2
Estradiol	affects binding, increases expression, affects cotreatment	2
Aflatoxin B1	decreases methylation, increases methylation	2
fluorene-9-bisphenol	increases expression	1
methylmercuric chloride	decreases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	affects cotreatment, increases expression	1
trichostatin A	increases expression, decreases expression	1
zinc chromate	increases abundance, increases expression	1
chromium hexavalent ion	increases abundance, increases expression	1
CGP 52608	affects binding, increases reaction	1
bisphenol S	increases expression	1
Arsenic	affects methylation	1
Dexamethasone	affects cotreatment, increases expression	1
Diethylhexyl Phthalate	decreases expression	1
Indomethacin	affects cotreatment, increases expression	1
Nickel	decreases expression	1
Progesterone	affects cotreatment, increases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

2 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04340856	Not specified	COMPLETED	Retrospective, Uncontrolled Cohort Study on the Therapy of Chronic Megalon
NCT07470892	Not specified	NOT_YET_RECRUITING	Preoperative Fish Oil PN and Prognosis After Constipation Surgery